Stephen Mandel’s AbbVie ABBV Stock Holding History

Stephen Mandel’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-5,247,201	Closed	-$303M	–	49
2014 Q3	$303M	Buy	+5,247,201	New	+$291M	1.18%	30

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock Group London, United Kingdom $210B AUM 15.76% 1-Year Est. Return

Stephen Mandel's ABBV Position: Q4 2014 in Review

Stephen Mandel sold out of AbbVie (ABBV) in Q4 2014, closing a stake of 5,247,201 shares — an estimated $303M sold.

Stephen Mandel first reported a position in ABBV in Q3 2014 and held it in 1 quarter. The position peaked at $303M in Q3 2014. 1,605 funds tracked by Wall St. Rank hold ABBV as of Q4 2014.

Stephen Mandel reported no remaining AbbVie position as of Q4 2014 after selling out during the quarter.
Stephen Mandel sold 5,247,201 AbbVie shares in Q4 2014, an estimated $303M.
Stephen Mandel first reported a position in AbbVie in Q3 2014 and held it in 1 quarter.
Stephen Mandel's AbbVie position peaked at $303M in Q3 2014.
1,605 funds tracked by Wall St. Rank held AbbVie as of Q4 2014.

Based on Lone Pine Capital's 13F filing for Q4 2014, filed 17 Feb 2015.